Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung CancerMehmet Altan, Gilberto Lopes, T Jeroen N Hiltermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2025
Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid TumorsIgnacio Melero, Josep Tabernero, Neeltje Steeghs, et al.
Nature Communications|May 15, 2024
CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional Phase 1 trialsNeil H Segal, Ignacio Melero, Victor Moreno, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2024
Plasma ctDNA as a Treatment Response Biomarker in Metastatic Cancers: Evaluation by the RECIST Working GroupAlexander W Wyatt, Saskia Litiere, Francois-Clément Bidard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid TumorsKyung Hae Jung, Patricia LoRusso, Howard Burris, et al.
The Lancet. Oncology|June 9, 2016
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trialScott J Antonia, José A López-Martin, Johanna Bendell, et al.
Cancer Research Communications|February 21, 2025
Safety and Antitumor Activity of a Novel aCD25 Treg Depleter RG6292 as a Single Agent and in Combination with Atezolizumab in Patients with Solid TumorsValentina Gambardella, Michael Ong, Maria E Rodriguez-Ruiz, et al.
Applied Clinical Informatics|September 11, 2024
Developing PRISM: A Pragmatic Institutional Survey and Bench Marking Tool to Measure Digital Research Maturity of Cancer CentersCarlos Berenguer Albiñana, Matteo Pallocca, Hayley Fenton, et al.
Nature Medicine|July 13, 2026
An anti-PMEL antibody-drug conjugate with a Gq/11 inhibitor payload in GNAQ/GNA11-mutant melanomas: a phase 1 trialMatteo S Carlino, Ellen Kapiteijn, Sophie Piperno-Neumann, et al.
The New England Journal of Medicine|February 5, 2025
Efficacy of Zenocutuzumab in NRG1 Fusion-Positive CancerAlison M Schram, Koichi Goto, Dong-Wan Kim, et al.
Pageof 16